Gilteritinib Qilu Pharmaceutical

Gilitinib is already on the market in China. Only imported original drugs are available, and there is no domestically produced Gilteritinib, and it is not included in medical insurance. Qilu Pharmaceutical is a domestic pharmaceutical manufacturer. It is understood that there is currently no domestic drug for giritinib produced by this pharmaceutical factory. Giritinib has been approved for use in patients with newly diagnosed AML (acute myeloid leukemia), specifically those who carry FLT3-ITD or FLT3-TKD gene mutations. The goals of treatment for newly diagnosed AML are to achieve remission, prolong progression-free survival (PFS), and improve overall survival. Giritinib is also approved for patients with relapsed/refractory AML, including those with FLT3-ITD or FLT3-TKD gene mutations.